Julia Delahousse

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 5

Top Topics

Advanced Cancer

Skeletal Muscle

Ejection Fraction

Top Venues

Journal for immunotherapy of cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Laurent Mathiot, David Combarel, Justin Cagnat, Julia Delahousse, Kaissa Ouali, Aurélien Marabelle, Yohann Loriot, Santiago Ponce, Stephane Champiat, Sophie Broutin, François-Xavier Danlos
Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors. Journal for immunotherapy of cancer 12 (5) (2024)
Laurent Mathiot, David Combarel, Justin Cagnat, Julia Delahousse, Kaissa Ouali, Aurélien Marabelle, Yohann Loriot, Santiago Ponce, Stephane Champiat, Sophie Broutin, François-Xavier Danlos
Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors. Journal for immunotherapy of cancer 12 (5) (2024)
Laurent Mathiot, David Combarel, Justin Cagnat, Julia Delahousse, Kaissa Ouali, Aurélien Marabelle, Yohann Loriot, Santiago Ponce, Stephane Champiat, Sophie Broutin, François-Xavier Danlos
Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors. Journal for immunotherapy of cancer 12 (5) (2024)
Laurent Mathiot, David Combarel, Justin Cagnat, Julia Delahousse, Kaissa Ouali, Aurélien Marabelle, Yohann Loriot, Santiago Ponce, Stephane Champiat, Sophie Broutin, François-Xavier Danlos
Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors. Journal for immunotherapy of cancer 12 (5) (2024)
Julia Delahousse, Charles Skarbek, Mélanie Desbois, Jean-Luc Perfettini, Nathalie Chaput, Angelo Paci
Oxazaphosphorines combined with immune checkpoint blockers: dose-dependent tuning between immune and cytotoxic effects. Journal for immunotherapy of cancer 8 (2) (2021)